Physician profile
Jonathan M Meyer
NPI 1003832809
$2,326,979.11
in general payments reported to CMS, 2019-2025
24 companies · $652K in 2025
The $652K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232K · 2020: $59K · 2021: $90K · 2022: $241K · 2023: $481K · 2024: $573K · 2025: $652K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Consulting Fee: $366K · Travel and Lodging: $118K · Honoraria: $69K · Food and Beverage: $37K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,115,350.12 |
| Consulting Fee | $366,267.85 |
| Travel and Lodging | $117,760.13 |
| Honoraria | $69,339.50 |
| Food and Beverage | $36,949.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $489,755.31 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $382,171.75 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370,732.11 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $362,880.20 | 2019-2025 | Ingrezza |
| Abbvie INC. | $173,194.35 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164,697.27 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $147,244.62 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $95,369.70 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $73,688.81 | 2019-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $20,257.45 | 2019-2023 | Abilify Maintena |
| Noven Pharmaceuticals, INC. | $13,276.00 | 2020-2021 | |
| Luye Pharma (USA) Ltd. | $9,900.00 | 2025 | Erzofri Extended-Release |
| Allergan, INC. | $6,929.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $5,247.73 | 2019-2025 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,752.91 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $3,655.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $2,777.50 | 2022 | |
| Tris Pharma INC | $144.83 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $85.13 | 2025 | Lumryz |
| Supernus Pharmaceuticals, INC. | $83.59 | 2025 | Qelbree |
| Shire North American Group INC | $43.14 | 2019 | |
| Biogen, INC. | $35.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.76 | 2022 | |
| Abbott Laboratories | $20.35 | 2023 | Cardiomems |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.